One is the sustaining activation of CD8+ cytotoxic T lymphocytes (CTLs) via the CD40L-CD40 and CD27-CD70 pathways and the promotion of antibody production against B cells via DC activation, and the other is the direct cytotoxicity toward cancer cells. This evidence concerns the gene CD8A and cancer.